SML0248
佐米曲普坦
≥98% (HPLC)
别名:
(4S)-4-((3-(2-(Dimethylamino)ethyl)-1H-indol-5-yl)methyl)-2-oxazolidinone, (S)-4-((3-(2-(Dimethylamino)ethyl)indol-5-yl)methyl)-2-oxazolidinone, 311C90
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C16H21N3O2
化学文摘社编号:
分子量:
287.36
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
MDL number:
产品名称
佐米曲普坦, ≥98% (HPLC)
InChI
1S/C16H21N3O2/c1-19(2)6-5-12-9-17-15-4-3-11(8-14(12)15)7-13-10-21-16(20)18-13/h3-4,8-9,13,17H,5-7,10H2,1-2H3,(H,18,20)/t13-/m0/s1
SMILES string
CN(C)CCc1c[nH]c2ccc(C[C@H]3COC(=O)N3)cc12
InChI key
ULSDMUVEXKOYBU-ZDUSSCGKSA-N
assay
≥98% (HPLC)
form
powder
optical activity
[α]/D -3 to -8°, c = 1 in methanol
color
white to beige
solubility
DMSO: ≥5 mg/mL
storage temp.
2-8°C
Quality Level
Gene Information
human ... HTR1B(3351), HTR1D(3352)
正在寻找类似产品? 访问 产品对比指南
Application
Zolmitriptan has been used as a 5-hydroxytryptamine receptor 1B (5-HT1B/D) activator to treat grafts to study its effects on the morphology of the ectopic eye.
Zolmitriptan has been used to induce hyper-innervation of transplants.
Biochem/physiol Actions
Zolmitriptan is a potent, selective. centrally and peripherally acting 5HT1B/1D receptor agonist.
Zolmitriptan is a selective serotonin receptor agonist of the 5HT1B and 5HT1D subtypes, both centrally and peripherally. It has been used clinically for the acute treatment of migraine attacks with or without aura and cluster headaches.
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
新产品
此项目有
Gianni Allais et al.
Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 32 Suppl 1, S99-104 (2011-05-06)
Menstrually related migraine (MRM) is a particularly difficult-to-treat pain condition, associated with substantial disability. Aim of this study was to compare the efficacy and safety of frovatriptan and zolmitriptan in the treatment of MRM attacks, analyzing data from a multicenter
Marek Gawel et al.
Expert opinion on pharmacotherapy, 6(6), 1019-1024 (2005-06-15)
Intranasal zolmitriptan has recently been launched in the US and Canada and is a novel formulation of the antimigraine drug zolmitriptan. This drug has been used extensively in its oral formulation. The intranasal formulation offers a more rapid onset of
Vincenzo Tullo et al.
Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 33 Suppl 1, S61-S64 (2012-06-01)
Migraine with aura affects ~20-30 % of migraineurs and it is much less common than migraine without aura. The aim of this study was to compare the efficacy of frovatriptan 2.5 mg and zolmitriptan 2.5 mg in the treatment of
C M Spencer et al.
Drugs, 58(2), 347-374 (1999-09-03)
Zolmitriptan is a selective serotonin 5-HT1B/1D receptor agonist ('triptan'). Its efficacy and tolerability have been assessed in a number of randomised, placebo-controlled, double-blind trials in large numbers of adults with moderate to severe migraine attacks. Oral zolmitriptan 2.5 and 5mg
Luana Lionetto et al.
Expert opinion on drug metabolism & toxicology, 8(8), 1043-1050 (2012-07-06)
Migraine is a multifactorial neurovascular disorder characterized by recurrent episodes of disabling pain attacks, accompanied with gastrointestinal, neurological systems dysfunction. The pharmacologic treatment of migraine is classically divided in the management of the acute attack and preventive strategies. Acute treatments
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持